CAR T-cell therapy is a potentially life-saving treatment for patients with certain hematologic malignancies. Yet, the logistical challenges and the need for specialized management of adverse events have limited its availability in community settings. In this episode, CANCER BUZZ speaks with Jeremy M. Pantin, MD, FACP, clinical director of the Adult Transplant and Cellular Therapy Program at TriStar Centennial Medical Center, part of the Sarah Cannon Transplant and Cellular Therapy Network. Dr. Pantin discusses the cancer center's community-based, outpatient model, impact on outcomes for patients with hematologic malignancies, and shares his perspective on future changes needed to help further expand access to CAR T-cell therapy.

"Education of community oncology staff at their offices—coordinators, nurses, physicians, advanced practice providers—also goes a long way in helping facilitate patients to be recognized when they are candidates for cell therapy." - Jeremy M. Pantin, MD, FACP

"It did not matter the distance to the center; did not matter the socioeconomic background. Many of the other factors one would think would lead to decreased access, we did not find among our centers. It was really the delay from consult to treatment." - Jeremy M. Pantin, MD, FACP

Guest:

Jeremy M. Pantin, MD, FACP

Clinical Director, Adult Transplant and Cellular Therapy Program

Sarah Cannon Transplant and Cellular Therapy Network At TriStar

Centennial Medical Center

Nashville, TN

Resources:

Bringing CAR T-Cell Therapies to Community Oncology

Outpatient Administration of Chimeric Antigen Receptor T-Cell Therapy Using Remote Patient Monitoring

FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor CAR T cell Immunotherapies